PO.CL11.01 · 临床研究

儿童癌症长期生存者中治疗相关克隆性造血影响的T细胞转录组

T-cell transcriptome affected by therapy-related clonal hematopoiesis in long-term survivors of pediatric cancers

海报缩略图:儿童癌症长期生存者中治疗相关克隆性造血影响的T细胞转录组
编号 5213 展板 4 时间 4/21 09:00–12:00 区域 Section 41 主讲 Nadezhda Terekhanova, PhD
分会场 Biological and Clinical Consequences of Cancer Therapy
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Nadezhda V. Terekhanova, Sivaraman Natarajan, Bensheng Ju, Kohei Hagiwara, Li Dong, Zhaoming Wang, Leslie L. Robison, John Easton, Jinghui Zhang

St. Jude Children's Research Hospital, Memphis, TN

摘要 Abstract

中文摘要
我们此前发表的关于圣裘德终生队列研究(SJLIFE)的工作——一个回顾性构建、对儿童癌症长期生存者进行前瞻性随访的队列——揭示了与既往放疗和化疗暴露相关的加速性克隆性造血(CH)现象。STAT3 Y640F是一个特异性与霍奇金淋巴瘤(HL)生存者既往丙卡巴肼暴露相关的热点突变,在SJLIFE队列中最为频繁。基于使用MissionBio平台在单细胞分辨率下对DNA扩增子和细胞表面蛋白进行的联合谱分析,我们在10例HL生存者中的6例的血液白细胞中发现了STAT3 Y640F突变。重要的是,STAT3 Y640F在聚集于CD8 T细胞内的细胞中富集,表明突变阳性细胞已重编程转录组,从而赋予其中一部分细胞选择性生长优势。为研究这一点,我们进行了PacBio scKinnex检测,以在单细胞水平生成全长转录组,从而实现CH突变与基因表达谱的整合。使用HL生存者血液样本的初步分析所得信息有限,因为由于突变频率低(≤1%)和STAT3表达,检测到的突变细胞很少。为富集突变细胞,我们对三个样本进行了CD8+ T细胞分选,随后进行scKinnex,获得了足够数量的突变细胞(每个样本14至26个细胞)用于基因表达分析。对每个分选样本,分析了4,396至5,416个细胞,按基因表达聚类揭示每个样本11-14个亚群。在标记基因表达状态的指导下,我们进行了细胞注释,识别出多个CD8 T细胞亚群,包括初始、中央记忆、效应记忆和终末分化效应记忆细胞。STAT3突变细胞仅存在于其中少数亚群中:这三个样本中分别为13个中的3个(23%)、14个中的1个(7%)和11个中的2个(18%),每个亚群中的平均频率为40%。几乎所有突变阳性簇均显示STAT3基因表达增加;其中五个此类簇中的四个(80%)表现出细胞毒性标志物的高表达,包括GZMB、GZMH、FGFBP2和NKG7,而其余一个则显示FOS/JUN通路应激反应标志物(JUN、JUNB和FOS)的高表达。据我们所知,这是首个表明CH突变能够赋予CD8 T细胞特定功能性细胞亚群选择性优势的研究,目前正在对这些细胞亚群中与STAT3 Y640F突变相关的基因调控网络变化进行分析。我们的研究还证明,细胞分选后进行scKinnex可以成为在单细胞分辨率下研究罕见CH突变在相关细胞类型中功能影响的有效策略。
查看英文原文 English abstract
Our previously published work on the St. Jude Lifetime Cohort Study (SJLIFE), a retrospectively constructed cohort with prospective follow-up of long-term survivors of pediatric cancer, unveiled the phenomenon of accelerated clonal hematopoiesis (CH) associated with prior exposure to radiotherapy and chemotherapy. STAT3 Y640F, a hotspot mutation specifically linked to prior exposure to procarbazine in Hodgkin Lymphoma (HL) survivors, was most frequent in the SJLIFE cohort. Based on joint profiling of DNA amplicons and cell-surface proteins at single cell resolution using the MissionBio platform, we found STAT3 Y640F mutation in blood leukocytes from 6 out of 10 HL survivors. Importantly, STAT3 Y640F was enriched in cells clustered within CD8 T-cells, indicating that mutation-positive cells have reprogramed the transcriptome that gave selective growth advantage to a subset of those cells. To investigate this, we performed PacBio scKinnex assay to generate full-length transcriptomes at single cell level, enabling integration of CH mutations with gene expression profiles. An initial analysis using blood samples of HL survivors yielded limited information as few mutant cells were detected due to the low mutation frequency (≤1%) and STAT3 expression. To enrich for the mutant cells, we performed sorting for CD8+ T-cells followed by scKinnex for three samples which yielded sufficient number of mutant cells (14 to 26 cells per sample) for gene expression analysis. For each sorted sample 4,396 to 5,416 cells were profiled, and clustering by gene expression revealed 11-14 subpopulations per sample. Guided by the expression status of marker genes, we performed cell annotation and identified multiple CD8 T-cell subsets, including naive, central memory, effector memory, and terminally differentiated effector memory cells. STAT3 mutant cells were present only in a few of these subpopulations: 3 out of 13 (23%), 1 out of 14 (7%), and 2 out of 11 (18%) in these three samples with an average frequency of 40% in each subpopulation. Nearly all mutant-positive clusters showed increased expression of STAT3 gene; four out of the five (80%) such clusters exhibited high expression of cytotoxic markers, including GZMB , GZMH , FGFBP2 and NKG7 , while the remaining one showed high expression of stress response markers from FOS/JUN pathway ( JUN , JUNB , and FOS ). To our best knowledge, this is the first study that shows CH mutation can confer selective advantage to specific functional cell subsets of CD8 T-cells and analysis of gene-regulatory network changes related to STAT3 Y640F mutation in those cell subpopulations is currently ongoing. Our study also demonstrates that cell sorting followed by scKinnex can be an effective strategy for studying the functional impact of rare CH mutations at the single cell resolution in relevant cell types.
利益披露 Disclosure
N. V. Terekhanova, None.. S. Natarajan, None.. B. Ju, None.. K. Hagiwara, None.. L. Dong, None.. Z. Wang, None.. L. L. Robison, None.. J. Easton, None.. J. Zhang, None.

← 返回 AACR 2026 检索